Form 8-K · Current Report · Filed 2025-05-08

Gilead Sciences Reports Voting Results from 2025 Annual Meeting

Gilead Sciences, Inc. held its 2025 annual meeting on May 7, 2025, where shareholders elected nine directors, ratified the selection of Ernst & Young LLP as the independent registered public accounting firm, approved the compensation of Named Executive Officers on an advisory basis, and rejected several stockholder proposals. The meeting was well-attended with a significant number of shares represented. Financial statements and exhibits were furnished as part of the filing.

Filer: Gilead Sciences Inc. GILD · NASDAQ
Filed: 2025-05-08
Accession: 0000882095-25-000015
CIK: 0000882095
Signal: Medium impactHealthcare
Source: Official filing on sec.gov ↗

Items reported

Item 5.07

Submission of Matters to a Vote of Security Holders

Director Elections Results Shareholder Rejection

Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$98.90

Next session

-2.0%

Since filing

+31.7%

Latest close

$130.21

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from GILD reporting the same item, with the next session's move:

2025-04-24Gilead Sciences Reports Q1 2025 Financial Results-3.0%

2025-02-11Gilead Reports Q4 and FY 2024 Results: Revenue Up, EPS Down+8.2%

2024-12-13Gilead Sciences Appoints New Chief Medical Officer-0.4%

2024-11-20Gilead Sciences Announces Issuance of $3.5B Senior Notes+2.3%

2024-11-06Gilead Sciences Reports Third Quarter 2024 Financial Results+8.5%

About Gilead Sciences Inc.

Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.

Exchange NASDAQ Industry Drug Manufacturers - General Company website ↗

Never miss another GILD filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts